Prot #2138-CL-0101: A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Exp

Project: Research project

Project Details

StatusActive
Effective start/end date4/15/24 → 4/15/27

Funding

  • ICON Clinical Research, LLC (Prot #2138-CL-0101 // Prot #2138-CL-0101)
  • Astellas Pharma Global Development, Inc. (Prot #2138-CL-0101 // Prot #2138-CL-0101)